Suppr超能文献

早期慢性肺部疾病新生儿的表面活性剂替代治疗

Surfactant replacement in neonates with early chronic lung disease.

作者信息

Pandit P B, Dunn M S, Kelly E N, Perlman M

机构信息

Department of Paediatrics, University of Toronto Perinatal Complex, Ontario, Canada.

出版信息

Pediatrics. 1995 Jun;95(6):851-4.

PMID:7761208
Abstract

OBJECTIVE

To study the effect of a single dose of exogenous bovine surfactant on oxygen and ventilatory requirements of neonates with early chronic lung disease.

STUDY DESIGN

Prospective pilot study.

SETTING

Three regional neonatal intensive care units.

METHODS

Infants 7 to 30 days old with birth weights less than 1500 g were eligible if they required a fraction of inspired oxygen (FIO2) of more than 0.4, had stable ventilatory requirements for 24 hours before study entry, and showed diffuse haziness on chest radiographs. Those with patent ductus arteriosus or active infection or those receiving steroid therapy were excluded. After treatment with the surfactant, differences in FIO2 and the ventilator efficiency index were analyzed using the Wilcoxon signed rank test.

RESULTS

Ten patients were recruited. Median values (range): birth weight, 693 g (530 to 1100 g); gestation, 25 weeks (24 to 27 weeks); and postnatal age at study entry, 13 days (9 to 30 days). The FIO2 decreased significantly between 0 and 1 hour after surfactant administration, from a median (range) of 0.67 (0.47 to 0.88) to 0.39 (0.28 to 0.63). This effect was sustained for 24 hours (median FIO2, 0.36). Although the FIO2 subsequently increased to 0.49 (range, 0.35 to 0.88) at 72 hours, it was significantly lower than that entry before the study. There was a trend toward an increase in the ventilator efficiency index at 24 and 48 hours.

CONCLUSIONS

A single dose of surfactant is effective in reducing oxygen requirements in neonates with early chronic lung disease. Surfactant replacement may be useful adjunctive therapy in these neonates.

摘要

目的

研究单剂量外源性牛肺表面活性物质对早期慢性肺疾病新生儿氧需求和通气需求的影响。

研究设计

前瞻性初步研究。

研究地点

三个地区性新生儿重症监护病房。

方法

出生体重小于1500g、年龄7至30天的婴儿,若吸入氧分数(FIO2)大于0.4,在研究入组前通气需求稳定24小时,且胸部X线片显示弥漫性模糊,则符合入选标准。排除动脉导管未闭或有活动性感染或正在接受类固醇治疗的婴儿。使用肺表面活性物质治疗后,采用Wilcoxon符号秩检验分析FIO2和通气效率指数的差异。

结果

招募了10名患者。中位数(范围):出生体重693g(530至1100g);孕周25周(24至27周);研究入组时的出生后年龄13天(9至30天)。给予肺表面活性物质后0至1小时内,FIO2显著下降,中位数(范围)从0.67(0.47至0.88)降至0.39(0.28至0.63)。这种效果持续24小时(FIO2中位数为0.36)。尽管72小时时FIO2随后升至0.49(范围为0.35至0.88),但仍显著低于研究前的水平。在24小时和48小时时,通气效率指数有增加趋势。

结论

单剂量肺表面活性物质可有效降低早期慢性肺疾病新生儿的氧需求。肺表面活性物质替代治疗可能是这些新生儿有用的辅助治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验